PEPG
PepGenCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
PEPG vs peer average
63/100
PEPG vs. peer average (C vs. D)
Grade spread
A 1 · B 1 · D 5 · F 3
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
RNA is the first available peer comparator.
Avidity is a direct DM1 operating comparator because PepGen identifies del-desiran/AOC 1001 as a Phase 3 clinical program competing against PepGen's DM1 candidate, making RNA the clearest category benchmark for speed and perceived efficacy leadership [#10-K-2026-03-04].
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
PEPG
PepGen
RNA
Atrium Therapeutics
Grade
C
D
Momentum
33
28
Value
58
57
Sentiment
64
51
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Mixed
Defensive
Grade position vs RNA
PEPG / RNA
Grade Position
In line
PEPG vs. peer average (C vs. D)
63/100
Momentum
33
PEPGValue
58
PEPGSentiment
64
PEPGRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs PEPG
RNA is the first peer returned for this comparison set.